{"organizations": [], "uuid": "ec60d00e566c74942884eab2122bf89f3879d1bd", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180306.html", "section_title": "Archive News &amp; Video for Tuesday, 06 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-fibrocell-announces-fda-allowance/brief-fibrocell-announces-fda-allowance-of-investigational-new-drug-application-for-fcx-013-idUSASB0C8YC", "country": "US", "domain_rank": 408, "title": "BRIEF-Fibrocell Announces FDA Allowance Of Investigational New Drug Application For FCX-013", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.989, "site_type": "news", "published": "2018-03-06T21:18:00.000+02:00", "replies_count": 0, "uuid": "ec60d00e566c74942884eab2122bf89f3879d1bd"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-fibrocell-announces-fda-allowance/brief-fibrocell-announces-fda-allowance-of-investigational-new-drug-application-for-fcx-013-idUSASB0C8YC", "ord_in_thread": 0, "title": "BRIEF-Fibrocell Announces FDA Allowance Of Investigational New Drug Application For FCX-013", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "fibrocell science inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 6 (Reuters) - Fibrocell Science Inc:\n* FIBROCELL ANNOUNCES FDA ALLOWANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR FCX-013 FOR THE TREATMENT OF MODERATE TO SEVERE LOCALIZED SCLERODERMA\n* FIBROCELL ANNOUNCES FDA ALLOWANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR FCX-013 FOR THE TREATMENT OF MODERATE TO SEVERE LOCALIZED SCLERODERMA\n* FIBROCELL SCIENCE - U.S. FDA GRANTED IND APPLICATION FOR FCX-013 TO BEGIN CLINICAL TRIALS FOR TREATMENT OF MODERATE TO SEVERE LOCALIZED SCLERODERMA\n* FIBROCELL SCIENCE - EXPECTS TO INITIATE ENROLLMENT FOR OPEN LABEL, SINGLE ARM PHASE 1/2 CLINICAL TRIAL IN Q3 2018 FOR FCX-013\n* FIBROCELL SCIENCE- INTENDS TO INCLUDE PEDIATRIC PATIENTS IN PHASE 2 POST APPROVAL OF SAFETY AND ACTIVITY DATA FROM ADULT PHASE 1 PATIENTS TO FDA Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-06T21:18:00.000+02:00", "crawled": "2018-03-07T19:25:04.003+02:00", "highlightTitle": ""}